Paclitaxel Releasing Hemodialysis
Shunt Balloon Dilatation Catheter


Less Shunt Restenosis improves Hemodialysis Patients’ Quality of Life!

The specifically designed and exclusively CE-Mark approved high pressure DCB for the treatment of shunt stenosis.

APERTO SHUNT DCB protects AV fistulas and shunt grafts from early restenosis.
For the prevention and successful dilatation of intimal hyperplasia.

Efficacy and Safety of Paclitaxel-Coated Balloon Angioplasty for Dysfunctional Arteriovenous Fistulas: A Multicenter Randomized Controlled Trial

Yanqi Yin - Yaxue Shi, et al., The American Journal of Kidney Diseases
P19-27.E1, JULY 01, 2021

AJKD Study Publication

Randomized clinical study results confirm APERTO as the first choice in the AVF stenosis treatment:

APERTO AVF RCT CHINA is the first AVF RCT study to achieve statistical superiority versus High Pressure POBA in the market.


APERTO DCB promises a prolonged Dialysis access survival.

Shunt restenosis represents a common threat to the function of arteriovenous fistulas (AVFs) and shunt grafts in patients on hemodialysis. Patients often develop a consecutive neointimal hyperplasia in hemodialysis access vessels as well as along the needle puncture site.

The new APERTO DCB Paclitaxel releasing, high pressure balloon dilatation catheter provides a dual shunt treatment quality for the prevention and dilatation of intimal hyperplasia. AVF or PTFE shunt graft venous outflow lesions can be treated very successfully by the new APERTO OTW leading to a substantial reduction of hemodialysis shunt restenosis, for a prolonged dialysis access survival.

APERTO DCB provides 2 x vessel protection
and long-term shunt-patency!

APERTO provides 2x vessel protection. APERTO optimizes the long-term anti-proliferative vessel wall protection, combined with a anti-inflammatory healing effect.

Hemodialysis vessel stenosis is typically treated by using a high pressure PTA dilatation balloon or alternatively a cutting balloon, which is applied to cut into highly calcified and fibrotic lesions. By applying the APERTO DCB, your shunt balloon dilatation is optimized by a 2 fold clinically important vessel wall protection.

1. Paclitaxel is anti-inflammatory 2. Paclitaxel is anti-proliferative

The APERTO OTW Shunt DEB demonstrates a long-term primary patency, and shunt survival of arterio-venous shunt grafts.

For the successful treatment of hemodialysis access stenosis
and recanalization of arterio-venous shunt grafts.

The new prohealing treatment of shunt stenosis.
Long-term shunt patency with anti-proliferative
vessel wall protection.

  • Conventional Mechanical Balloon Angioplasty
  • Trauma
  • Inflammation
  • Neointimal Hyperplasia
  • Restenosis
  • Short-Term Repeat Intervention
  • High Patient Cost
  • APERTO Angioplasty with Prohealing Local Drug Delivery
  • Trauma
  • Anti-Inflammatory Action !
  • Anti-Proliferative Action !
  • Healing !
  • Long-Term Shunt Patency !
  • Cost Saving !

Safe Drug Coating Technology
for advanced treatment quality.

APERTO provides a safe PTX drug release to treat shunt stenosis.
Amorphous coating with no PTX particulates protect from potential risk of micro- embolization.

APERTO ‘SAFEPAX’ technology utilizes the clinically important, stable amorphous PTX coating which was specifically developed for the protection from downstream effects to minimize any risk of micro-embolization in the arterio venous system.

About safepax

Cardionovum clinical program of the APERTO Paclitaxel releasing high pressure shunt balloon dilatation catheter.

Clinical Program
go top